Efficacy and safety updates of poly ADP-ribose polymerase (PARP) inhibitor maintenance in ovarian cancer from ASCO 2020

Int J Gynecol Cancer. 2020 Aug;30(8):1256-1257. doi: 10.1136/ijgc-2020-001723. Epub 2020 Jul 9.

Authors

Ainhoa Madariaga¹, Luisa Bonilla¹, Michelle McMullen¹, Amit M Oza¹, Stephanie Lheureux²

Affiliations

¹ Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
² Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada Stephanie.Lheureux@uhn.ca.

PMID: 32646863
DOI: 10.1136/ijgc-2020-001723

No abstract available

Keywords: ovarian cancer.

MeSH terms

Clinical Trials, Phase III as Topic
Female
Humans
Maintenance Chemotherapy
Ovarian Neoplasms / drug therapy*
Poly(ADP-ribose) Polymerase Inhibitors / adverse effects
Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use*
Retreatment

Substances

Poly(ADP-ribose) Polymerase Inhibitors